– Series Will Culminate in a Virtual R&D Day on December 15, 2022 –
CAMBRIDGE, Mass., September 19, 2022–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 9th annual series of "RNAi Roundtable" webinars over the coming weeks. The series will offer presentations from Alnylam scientists and program leaders who will review recent progress in a selection of the Company’s pipeline programs and platform innovations, as well as medical thought leaders who will provide their perspectives on clinical developments and unmet needs. Each event will be webcast live on the Investors section of the Company’s website at investors.alnylam.com/events, and a replay will be posted on the Alnylam website approximately three hours after each event.
The 2022 RNAi Roundtable schedule is as follows:
Cemdisiran, in Development for the Treatment of IgA Nephropathy (IgAN) and Other Complement-Mediated Diseases
Tuesday, September 27, 10:00 am ET
Alnylam Engine for Sustainable Innovation: Leadership in RNAi Platform and Human Genetics
Friday, October 21, 10:00 am ET
CNS Delivery and ALN-APP, in Development for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Tuesday, November 1, 11:00 am ET
Please visit the Capella section of our website for the latest information regarding webcast dates.
The Company also announced today that it plans to host a virtual R&D Day event on the morning of Thursday, December 15, 2022. Alnylam management will be joined by external guest speakers for a review of the Company’s RNAi pipeline and platform activities, including advancements in its TTR franchise programs. Additional details to follow.
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran), and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005315/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you…
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. By comparison, an…
The city’s fire department is looking to prevent 911 calls before they happen with a new community paramedic program that offers in-home visits.
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than…
Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.
A Food and Drug Administration advisory committee is set to meet this week to discuss three cancer therapies. The Oncologic Drugs Advisory Committee is set to meet Wednesday to vote whether the benefits of Spectrum Pharmaceuticals Inc.'s treatment of patients with certain types of non-small cell lung cancer outweigh the risks. The same day the committee is also set to discuss Pepaxto, Oncopeptides AB' investigational multiple myeloma treatment that received an accelerated approval in early 2021.
Shannon Sharpe says getting tested early may have saved his life.
As a new study confirms drinking too much really does make you look older, Lisa Salmon looks into other lifestyle factors that may contribute too
Sharply rising cases of some sexually transmitted diseases — including a 26% rise in new syphilis infections reported last year — are prompting U.S. health officials to call for new prevention and treatment efforts. “It is imperative that we … work to rebuild, innovate, and expand (STD) prevention in the U.S.,” said Dr. Leandro Mena of the U.S. Centers for Disease Control and Prevention in a speech Monday at a medical conference on sexually transmitted diseases. Infections rates for some STDs, including gonorrhea and syphilis, have been rising for years.
When should you get a flu shot? And can you get a flu shot at the same time as the Omicron booster? Here’s what experts say.
Flu season is approaching in the United States. Here's what you can expect this year — and when to get your flu vaccine to help you stay safe.
Former White House press secretary Sarah Sanders, a Republican who is running for governor in Arkansas, was released from a hospital Saturday after undergoing surgery for thyroid cancer.
Long COVID experts, patients, and advocates say the U.S. government isn't doing enough to prevent the condition and support people with it.
Free of charge resource My Special Aflac Duck® helps comfort 50 pediatric cancer and sickle cell patients in Louisiana
The vegetable was shown to lower blood sugar levels and cholesterol levels
It’s no secret that stress can take a toll on our health in many ways. Mentally, it can lead to anxiety and depression, burnout at work, and feeling irritable and overwhelmed. Physically, it can cause fatigue, trouble sleeping and appetite changes. When stress becomes chronic and cortisol levels …
Breakfast is deemed the "most important meal of the day" by many experts for a reason, as skipping it may be linked to health issues such as slow metabolism, weight gain, and even an increased risk of type 2 diabetes. This morning meal is particularly important for those who currently have diabetes. Eating early and having a meal that is low-carb and high-fat have been shown to support blood sugar levels throughout the day. On the other hand, missing out on breakfast may make it harder to keep y
Story at a glance People on the autism spectrum may also have varying co-occurring disorders and psychiatric conditions. An analysis of more than 4,600 autistic adults finds differences in the group that was diagnosed during childhood and the group diagnosed at age 21 or older. This may have implications for past studies in adults with…
"This is unreal," she says. "Best thing I've ever used, hands down."
It has long been thought that the answer to many of life’s problems is a good cup of tea.